Tilray Brands Sees Opportunity in Cannabis Rescheduling -- Market Talk
Dow Jones01-09
1715 ET - Tilray Brands Chief Executive Irwin Simon spoke in favor of President Trump's directive to reschedule marijuana. In December, the president signed an executive order directing the Attorney General to expedite the process of making marijuana a Schedule III drug, which is defined as having a moderate or low risk of dependence, from a Schedule I. Simon said a rescheduling would pave the way for more research and better patient access to medical cannabis in the U.S. Tilray can leverage its experience researching and developing medical marijuana as the regulatory landscape progresses, Simon said. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
January 08, 2026 17:15 ET (22:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
